Coagulation Disorders in Patients With Cirrhosis
Publication Date: September 24, 2021
Key Points
Key Points
- Significant alterations in laboratory parameters — such as platelet count (PLT) and prothrombin time/international normalized ratio (PT/INR) — routinely accompany cirrhosis.
- However, the risks of both bleeding and thrombosis are not accurately quantitated by standard testing in this population.
- The best strategies to identify patients at risk for bleeding or thrombosis, to provide appropriate prophylaxis in patients at risk for clinically significant bleeding, to screen for and treat portal vein thrombosis, and to prevent clinically significant thromboembolic events are currently unknown.
Diagnosis
...gnosis...
...ting Strategy
...isco-elastic Testing (VET)In patients...
.../INRIn patients with stable cirrhosi...
Portal Vein Thrombosis (PVT) Screeni...
...ith cirrhosis, the AGA suggests against ro...
Treatment
...reatme...
...rocedure Prophylaxis...
...or Fresh Frozen Plasma (FFP)In patients w...
...hrombopoietin receptor agonist (TPO-Ras)In patien...
...us Thromboembolism (VTE) Prophylax...
...d patients with cirrhosis and who otherwise meet...
...ubacute Non-tumoral Portal Vein Thr...
...th cirrhosis and acute or subacute nontumoral P...
...Fibrillation...
...ith cirrhosis and atrial fibrillation with...
...ocedure Risk StratificationHaving trouble...